orted redness, itching, pain, and/or swelling where the injection was given. You should not take ENBREL if you have a serious infection or are allergic to ENBREL or its ingredients. If you develop a serious or unusual infection while on ENBREL, you should tell your doctor right away. The long-term effects of treatments like ENBREL on serious infection, malignancy, or autoimmune disease are unknown. If you have questions about this or any of the above, be sure to discuss them with your doctor. Important Product Information can be obtained at www.enbrel.com.

ENBREL is manufactured by Immunex Corporation, Seattle, Washington. Immunex and Wyeth-Ayerst Pharmaceuticals are marketing ENBREL in North America. Other Wyeth-Ayerst affiliates are marketing ENBREL outside of North America.

Immunex is a biopharmaceutical company dedicated to developing immune system science to protect human health. The company's products offer hope to patients with cancer and inflammatory and infectious diseases.

Wyeth-Ayerst Pharmaceuticals, a division of American Home Products Corporation (AHP), is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines, and generic pharmaceuticals.

American Home Products owns a majority interest in Immunex. AHP is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. It is also a leader in vaccines, biotechnology, agricultural products, and animal health care.

'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
6-Apr-1999

Page: 1 2
Related medicine news :

1. ENBREL (etanercept) long-term clinical trial data
2. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
3. Circulation publishes phase I study of ENBREL in patients with chronic heart failure
4. ENBREL (Etanercept) Receives FDA Approval For Treatment Of Juvenile Rheumatoid Arthritis
5. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis
6. ENBREL Phase III Data Published In Annals Of Internal Medicine
7. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
8. Patient with drug-resistant form of HIV identified
9. Patient knows best when it comes to ulcerative colitis, U-M study finds
10. Patients with cancer have highly increased risk for blood clots
11. Patients with previous heart attacks may not benefit from pacemaker implant